Neha S Mangini1, Robert Wesolowski2, Bhuvaneswari Ramaswamy2, Maryam B Lustberg2, Michael J Berger3. 1. The James Cancer Hospital at the Ohio State University, Columbus, OH, USA. 2. The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 3. The James Cancer Hospital at the Ohio State University, Columbus, OH, USA michael.berger@osumc.edu.
Abstract
OBJECTIVE: To review palbociclib, a novel small-molecule inhibitor of cyclin-dependent kinases 4 and 6, and its current place in therapy for the treatment of hormone receptor (HMR)-positive, human epidermal growth factor receptor 2 (Her2)-negative advanced breast cancer. STUDY SELECTION AND DATA ABSTRACTION: Four phase I trials, 2 phase II trials, and 1 phase III trial were identified from May 2004 to May 2015 using PubMed, American Society of Clinical Oncology (ASCO) abstracts, and European Society of Medical Oncology (ESMO) abstracts. DATA SYNTHESIS: In the first-line setting, the phase II PALbociclib: Ongoing trials in the Management of breast cAncer (PALOMA)-1 trial randomized patients to receive letrozole alone or letrozole plus palbociclib 125 mg daily for 3 weeks, followed by 1 week off, as initial therapy for advanced breast cancer. The investigator-assessed median progression-free survival (PFS) was 20. 2 months for the combination versus 10.2 months for letrozole alone (hazard ratio [HR] = 0.488; 95% CI = 0.319-0.748; 1-sided P = 0.0004). The ensuing Food and Drug Administration approval of palbociclib was given a "breakthrough therapy" designation, where preliminary evidence suggests substantial improvement over existing therapies for a serious or life-threatening disease. A confirmatory phase III trial, PALOMA-2, is under way. In patients who were previously treated with endocrine therapy for advanced breast cancer, the phase III PALOMA-3 trial randomized patients to fulvestrant plus palbociclib versus fulvestrant plus placebo. The investigator-assessed median PFS at the time of a preplanned analysis was 9.2 months with palbociclib-fulvestrant compared with 3.8 months with placebo-fulvestrant (HR = 0.42; 95% CI = 0.32-0.56; P < 0.001). CONCLUSIONS:Palbociclib, the first-in-class CDK4/6 inhibitor, significantly extended PFS in combination with endocrine therapy in the first and subsequent lines of treatment for HMR-positive, Her2-negative advanced breast cancer.
RCT Entities:
OBJECTIVE: To review palbociclib, a novel small-molecule inhibitor of cyclin-dependent kinases 4 and 6, and its current place in therapy for the treatment of hormone receptor (HMR)-positive, humanepidermal growth factor receptor 2 (Her2)-negative advanced breast cancer. STUDY SELECTION AND DATA ABSTRACTION: Four phase I trials, 2 phase II trials, and 1 phase III trial were identified from May 2004 to May 2015 using PubMed, American Society of Clinical Oncology (ASCO) abstracts, and European Society of Medical Oncology (ESMO) abstracts. DATA SYNTHESIS: In the first-line setting, the phase II PALbociclib: Ongoing trials in the Management of breast cAncer (PALOMA)-1 trial randomized patients to receive letrozole alone or letrozole plus palbociclib 125 mg daily for 3 weeks, followed by 1 week off, as initial therapy for advanced breast cancer. The investigator-assessed median progression-free survival (PFS) was 20. 2 months for the combination versus 10.2 months for letrozole alone (hazard ratio [HR] = 0.488; 95% CI = 0.319-0.748; 1-sided P = 0.0004). The ensuing Food and Drug Administration approval of palbociclib was given a "breakthrough therapy" designation, where preliminary evidence suggests substantial improvement over existing therapies for a serious or life-threatening disease. A confirmatory phase III trial, PALOMA-2, is under way. In patients who were previously treated with endocrine therapy for advanced breast cancer, the phase III PALOMA-3 trial randomized patients to fulvestrant plus palbociclib versus fulvestrant plus placebo. The investigator-assessed median PFS at the time of a preplanned analysis was 9.2 months with palbociclib-fulvestrant compared with 3.8 months with placebo-fulvestrant (HR = 0.42; 95% CI = 0.32-0.56; P < 0.001). CONCLUSIONS:Palbociclib, the first-in-class CDK4/6 inhibitor, significantly extended PFS in combination with endocrine therapy in the first and subsequent lines of treatment for HMR-positive, Her2-negative advanced breast cancer.
Authors: Patrick J Roberts; John E Bisi; Jay C Strum; Austin J Combest; David B Darr; Jerry E Usary; William C Zamboni; Kwok-Kin Wong; Charles M Perou; Norman E Sharpless Journal: J Natl Cancer Inst Date: 2012-02-01 Impact factor: 13.506
Authors: Søren M Johnson; Chad D Torrice; Jessica F Bell; Kimberly B Monahan; Qi Jiang; Yong Wang; Matthew R Ramsey; Jian Jin; Kwok-Kin Wong; Lishan Su; Daohong Zhou; Norman E Sharpless Journal: J Clin Invest Date: 2010-06-23 Impact factor: 14.808
Authors: Kris Ann P Schultz; Joseph Petronio; Anne Bendel; Richard Patterson; David J Vaughn Journal: Pediatr Blood Cancer Date: 2014-11-21 Impact factor: 3.167
Authors: Keith T Flaherty; Patricia M Lorusso; Angela Demichele; Vandana G Abramson; Rachel Courtney; Sophia S Randolph; M Naveed Shaik; Keith D Wilner; Peter J O'Dwyer; Gary K Schwartz Journal: Clin Cancer Res Date: 2011-11-16 Impact factor: 12.531
Authors: John F R Robertson; Justin P O Lindemann; Antonio Llombart-Cussac; Janusz Rolski; David Feltl; John Dewar; Laura Emerson; Andrew Dean; Matthew J Ellis Journal: Breast Cancer Res Treat Date: 2012-10-13 Impact factor: 4.872
Authors: Richard S Finn; Judy Dering; Dylan Conklin; Ondrej Kalous; David J Cohen; Amrita J Desai; Charles Ginther; Mohammad Atefi; Isan Chen; Camilla Fowst; Gerret Los; Dennis J Slamon Journal: Breast Cancer Res Date: 2009 Impact factor: 6.466
Authors: G K Schwartz; P M LoRusso; M A Dickson; S S Randolph; M N Shaik; K D Wilner; R Courtney; P J O'Dwyer Journal: Br J Cancer Date: 2011-05-24 Impact factor: 7.640
Authors: Alan Umfress; Sarbjit Singh; Kevin J Ryan; Ayanabha Chakraborti; Florian Plattner; Yogesh Sonawane; Jayapal Reddy Mallareddy; Edward P Acosta; Amarnath Natarajan; James A Bibb Journal: Front Pharmacol Date: 2022-05-12 Impact factor: 5.988
Authors: Sandeep Rana; Yogesh A Sonawane; Margaret A Taylor; Smitha Kizhake; Muhammad Zahid; Amarnath Natarajan Journal: Bioorg Med Chem Lett Date: 2018-10-15 Impact factor: 2.823
Authors: Christina Y Yim; David J Sekula; Mary P Hever-Jardine; Xi Liu; Joshua M Warzecha; Janice Tam; Sarah J Freemantle; Ethan Dmitrovsky; Michael J Spinella Journal: Cancer Res Date: 2016-02-02 Impact factor: 12.701
Authors: Traci L Kruer; Susan M Dougherty; Lindsey Reynolds; Elizabeth Long; Tanya de Silva; William W Lockwood; Brian F Clem Journal: PLoS One Date: 2016-11-10 Impact factor: 3.240
Authors: Mariane Teodoro Fernandes; Jacob J Adashek; Carmelia Maria Noia Barreto; Ana Cláudia Barbin Spinosa; Barbara de Souza Gutierres; Gilberto Lopes; Auro Del Giglio; Pedro Nazareth Aguiar Journal: Drugs Context Date: 2018-11-05
Authors: Johannes Tobias Thiel; Adrien Daigeler; Jonas Kolbenschlag; Katarzyna Rachunek; Sebastian Hoffmann Journal: Cancers (Basel) Date: 2022-07-12 Impact factor: 6.575
Authors: Ann M Mazzella Ebstein; Margaret Barton-Burke; Venice Anthony; Andrea Smith; Zhigang Zhang; Mark Robson Journal: J Adv Nurs Date: 2020-11-27 Impact factor: 3.187